Earlier today, Avant Diagnostics,
Inc. (OTCQB: AVDX) announced that it will present at the SeeThruEquity &
The Brewer Group 2nd Annual Innovations Investor Conference, which will take
place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a
presenter, Avant will be provided with a 30-minute time slot with which to
present to an audience of investors and industry professionals. The company’s
management team is also expected to be available for one-on-one meetings with
institutional investors attending the event.
To view a complete list of
presenting companies, visit http://steconference.com/presenting-companies
This announcement follows last
month’s news that Avant has entered into a letter of intent to merge with
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience
Holdings, Inc. (OTCQX: AMBS). The proposed merger is expected to create opportunities
for the combined company to progress the development of highly valuable
diagnostic assets – including Avant’s OvaDx® large panel biomarker test for use
in monitoring women at a heightened risk for ovarian cancer, as well as
Amarantus Diagnostics’ MSPrecise® diagnostic assay for multiple sclerosis and
LymPro Test® flow cytometry assay for Alzheimer’s disease.
“After exploring numerous avenues
for implementing Avant’s OvaDx® development and commercialization strategy, it
is clear that combining Avant’s and Amarantus’ diagnostic assets and core
competencies forms a platform that provides maximum value to our collective
shareholders,” Gregg Linn, president and chief executive officer of Avant,
stated in a recent news release. “The collective diagnostic assets will create
a truly unique opportunity to implement our respective missions of saving and
enhancing lives through early detection of disease in oncology and neurology.”
SeeThruEquity, a leading
independent equity research and corporate access firm, released a report
studying the potential effects of the Avant merger last month. Among the
highlights, the SeeThruEquity report inferred that, when completed, the
proposed merger “will allow them to progress at a much faster pace and to
develop valuable diagnostic assets in areas of oncology and neurology.” The
report went on to note that the combined assets of Avant and Amarantus
Diagnostics “have the potential to improve the practice of medicine by
providing new proprietary diagnosis and monitoring tools for oncologists and
neurologists.”
If approved for commercialization,
OvaDX, in particular, is expected to offer a clear improvement to the current
diagnostic standard by substantially improving the accuracy of diagnosis and
allowing for a more effective therapeutic triaging and intervention strategy.
It’s estimated that the market opportunity for OvaDx is $50 million annually as
a diagnostic test for ovarian cancer, and this opportunity would expand to over
$2 billion annually if it were to be approved as a generalized screening and/or
monitoring tool.
For more information, visit the
company website at www.avantdiagnostics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment